Sponsors keep asking what ANMAT requires for clinical trials in Argentina as if one ninety-day bar covered ethics, investigation authorization, investigational import, and later commercial registro. It does not. ANMAT is one agency name on two files. Confusing them is how an Argentina Gantt goes soft.

I am Julio Martinez-Clark, CEO of bioaccess®. This checklist is for medical-device clinical-investigation filings in Argentina. It is grounded in the live ANMAT trial authorization vs registro post, the investigational import guide, and the market-access hub. It is not a quote and not legal advice. Confirm every instrument against ANMAT’s current published texts before you file.

Separate the two ANMAT files first

Write two columns on one page before translators start:

1. Investigation file. ANMAT clinical-investigation authorization for a first-in-human (FIH) or early feasibility study (EFS), plus independent ethics review under ISO 14155 and the Declaration of Helsinki, and provincial oversight where it applies (for example Buenos Aires). Success criterion: authorized research use of the named investigational article.
2. Registro file (commercial, later or parallel only if truly in scope). Sanitary registration for Classes I–IV under Disposición ANMAT N° 64/2025, including the simplified declaración jurada (DDJJ) route for CE-marked Class I/II through HELENA, with a local authorized representative / Technical Director ANMAT will treat as responsible for that certificate. Success criterion: a selling license — not a trial letter.

If the board slide says “ANMAT approved,” ask which ANMAT. Trial authorization is not a selling license.

Governing desks on the investigation track

• ANMAT — Dirección de Investigación Clínica. Disposición ANMAT 7516/2025 Article 5 assigns clinical-investigation evaluation to that directorate. The Colombia execution pillar already notes that disposition states no binding day-count for that evaluation desk in the same way some markets publish one; Argentina’s published planning framework for device investigations on our Argentina trial page remains the 90-business-day statutory review target that pauses for RFIs. FIH/EFS device studies often exceed that target. Treat 90 business days as a planning framework, not a guaranteed total start-up time.
• Independent ethics committee. Protocol, Spanish informed consent, and investigator packet. Ethics is a gate on the trial track, not a commercial license.
• Provincial oversight where required. File federal, ethics, and provincial packages in parallel when the study design allows it. Sequential filing adds calendar the statutory target never promised to absorb.
• Investigational import. Authorization linked to the ANMAT trial approval, through a licensed importer of record, with a device-level manifest. A commercial registro number does not clear investigational kits. Argentina’s import documentation is exacting — reconcile every document before filing (see the regional import guide).

Submission checklist (investigation dossier)

Assemble the universal FIH core once, then layer Argentina’s desks. Do not invent form codes that are not on the live bioaccessla.com pages — use this operator checklist against ANMAT’s current published requirements at filing time.

What this checklist is not

• It is not the commercial Classes I–IV / HELENA map under Disposición 64/2025. That is the market-access track and the live ANMAT registration checklist.
• It is not an importer-of-record substitute for a sanitary registration holder. Argentina is a strict single-IoR example on the commercial track (authorized representative under Disp. 64/2025). That holder conversation belongs on market access. It does not clear investigational freight for a FIH.
• It does not claim ANMAT is a PAHO/WHO Level 4 authority, and it does not invent an ICH-member claim — those claims are not published on this site.

Import: investigational units are not the registro SKU

Name the trial importer before ethics stamps the protocol. Map every investigational model, accessory, and spare to the investigation-authorized list. Outer labels must read as investigational. After last patient, close investigational inventory under the trial rules. Leaving units “for the hospital” without a new sanitary path is a new regulatory event, not a courtesy.

Hand-carry is not the plan. Formal, traceable importation tied to the trial authorization is required across Latin America; Argentina is not an exception.

If the Argentina FIH must support a U.S. file

Design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States): GCP, independent ethics review, and a device comparable to the version you will put in front of FDA. ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. A clean ANMAT investigation letter does not replace an inspectable trial master file. Keep device accountability, deviation logs, monitoring reports, ethics correspondence, and provincial letters in one place from day one. Eligibility of foreign data under § 812.28 is not a clearance prediction.

Common rejection / delay patterns

• One 90-day bar for both desks. Treating the statutory trial review target as if it also covered Classes I–IV commercial registration. Higher-risk commercial work often runs several months on experience, not on the trial clock.
• Registro number on investigational freight. Using a commercial ANMAT certificate for a predicate or related model to move FIH units.
• One Spanish translation for both desks. Ethics/investigation language is not the commercial IFU ANMAT will later lock on a registro.
• Importer named after first patient. Import documentation then becomes the critical path the ethics letter cannot fix.
• RFI pause ignored on the Gantt. The 90-business-day target pauses for requests for information. Budget response time.

One-page gate before first patient in Argentina

• Authority map: ANMAT investigation + independent ethics (+ provincial where required) versus commercial registro under Disp. 64/2025 / HELENA only if launch is truly in scope this year.
• Same protocol version and same Spanish informed-consent text across federal, ethics, and provincial packages.
• Investigational importer named, with the document that ties the shipment to the investigation authorization.
• Device list complete, including accessories.
• ISO 14155 file owner who can produce monitoring, accountability, and ethics letters within 48 hours if FDA or a notified body asks.
• Commercial holder (optional, separate): Argentine authorized representative / Technical Director kept off the FIH critical path until first patient is locked.

Related reading on bioaccessla.com

• ANMAT trial authorization vs registro
• Importing investigational devices into Latin America
• Universal LATAM FIH submission package
• Independent sanitary registration holder strategy
• Medical device registration & market access · Argentina regulatory guide

Planning an Argentina FIH or EFS investigation file — separate from registro? bioaccess® runs FIH/EFS execution across Latin America, including Argentina from Miami, and holds LATAM registration/IOR work as a separate market-access track. Contact Julio Martinez-Clark, Co-Founder & CEO, at jmclark@bioaccessla.com or +1 (954) 903-7210. More at bioaccessla.com/roadmap.

Frequently asked questions

What are ANMAT requirements for clinical trials in Argentina?

For devices, expect an ANMAT clinical-investigation file evaluated via the Dirección de Investigación Clínica (Disposición 7516/2025 Art. 5), independent ethics review, provincial filings where required, investigational labeling and import tied to the trial authorization, and an ISO 14155-ready trial master file. Commercial registro under Disposición 64/2025 / HELENA is a second petition.

Does the 90-business-day clock cover commercial registration?

No. The 90-business-day statutory target on our Argentina investigation pages is a planning framework for the trial review that pauses for RFIs. Classes I–IV registro is a separate file and clock.

Can we use a commercial ANMAT number to import FIH units?

No. Investigational units need import authorization linked to the trial approval. A registro number for a related commercial SKU does not clear the investigational article.

Is the registration holder the same as the trial importer?

Not automatically. Argentina’s commercial track is a strict single-IoR / authorized-representative posture under Disp. 64/2025. Name the trial importer for the investigation; keep the sanitary registration holder on the market-access track.

Will FDA accept Argentina FIH data?

Foreign clinical data may be eligible for FDA consideration under 21 CFR § 812.28 when GCP, ethics, and device comparability are documented. Eligibility is not a clearance or approval prediction.

The fastest way to lose control of a Latin America launch is to let the first distributor become the sanitary registration holder. The commercial conversation sounds efficient: “They already import, they already know COFEPRIS / INVIMA / ANVISA, put the certificate in their name.” Six months later the independent registration holder Latin America medical device option is gone, and every channel change becomes a regulatory project. This brief is how manufacturers avoid that lock-in — and how independent third-party titularidad keeps multi-distributor agility intact.

I am Julio Martinez-Clark, CEO of bioaccess®. We hold registrations through our own local entities for the manufacturer’s benefit. The public product card is the LATAM Launch Subscription at USD 7,500 per year per country for the first device family (published 23 August 2026). This page is strategy, not a quote. Confirm country-specific holder rules in the proposal.

1. The distributor-as-holder trap

Every major Latin American health authority ties a device registration to an in-country legal entity. That entity is the titular, detentor, representante autorizado, or registration holder. On that name sit tecnovigilancia, answers to the authority, variations, renewals, and — in several markets — importation rights. The distributor is a different job: sells, invoices, trains, services. When both jobs sit in one company, you do not have a channel partner. You have a partner who also owns the regulatory asset.

How the trap usually forms:

• Speed bias. The commercial team wants a LOI this quarter. The distributor offers to “handle registro.” Filing in their name is faster than standing up an independent holder — until you need to exit.
• Invoice confusion. Government fees and agent retainers get bundled into the distribution margin. Finance never sees a separate holder line, so nobody owns the certificate as an asset.
• Assumed portability. Teams assume “we can transfer later.” In many markets, transfer is a cesión de derechos, a new registro, or both — with months of downtime and a second full dossier.
• Single-door import. When the holder is also the exclusive importer, terminating the commercial relationship can strand inventory and freeze new shipments even if patients and hospitals still want the product.

The operating rule is simple: holder and distributor are separate roles unless you deliberately choose otherwise. Write that into the distribution LOI before anyone files. If the LOI is silent, the first filing will decide for you.

2. The cost of transferring registrations

Transfer cost is not only the government fee. It is calendar, dossier rebuild, and commercial interruption.

Mexico (COFEPRIS). The named titular on the Registro Sanitario is the sanitary face of the product. If the distributor is the name on the public Visor de Registros Sanitarios de Dispositivos Médicos, channel termination does not move the certificate. You negotiate a cesión or re-register. Either path needs a complete technical file, updated labels, and a vigilance handoff. While that runs, the outgoing holder still owns the legal duties — including tecnovigilancia under the applicable Mexican framework (including NOM-240-SSA1-2012 expectations for the titular).

Brazil (ANVISA). RDC No. 751 of 15 September 2022 names a single detentor de registro. The foreign manufacturer cannot be that detentor. Changing detentor is a regulated event, not a contract amendment. RDC 270/2019 already lets one detentor authorize several importers without re-registering the device — which is exactly why an independent Brazil Registration Holder is the correct design and a distributor-detentor is expensive to unwind.

Colombia (INVIMA). Decreto 4725 of 2005 is the sanitary-registration statute. INVIMA contemplates one titular with the ability to work through importers. Handing titularidad to the first commercializer turns every later distributor change into a regulatory file. Colombia remains a core market-access geography for bioaccess®; keep the commercial registro on an independent holder even when investigation work sits elsewhere.

Central America and single-representative markets. Panama (Ley 90 of 2017 and Decreto Ejecutivo No. 490 of 4 October 2019), El Salvador (SRS / DNM commercial track), Dominican Republic (DIGEMAPS), and similar single-authorized-representative models make holder changes especially painful: the representative is often titular and importer in one. Changing AAR frequently means registering again. Budget that as a new market entry, not a paperwork afternoon.

Hidden line items on every transfer. Certified Spanish or Portuguese retranslation if the outgoing distributor owned the glossary; new label artwork; updated importation permits; training the new vigilance contact; explaining to hospital procurement why the sanitary number’s legal face changed. Sponsors who “saved” a year-one holder fee typically spend it back in year-two exit costs — plus lost quarters of revenue.

3. Country titularidad frameworks (INVIMA, COFEPRIS, ANVISA, Central America)

Classification and holder rules diverge. Do not paste a single “Class II + local agent” row across nineteen countries.

COFEPRIS (Mexico). Reglamento de Insumos para la Salud Article 83 uses a three-class logic where duration-in-body and novelty drive Class II versus Class III. A Mexico Registration Holder that is not the exclusive distributor can name several distributors and importers on one certificate. That is the structural reason independent titularidad pays for itself in Mexico: one sanitary face, many commercial doors. Check the named titular on the public visor once the registro is vigente.

ANVISA (Brazil). Four classes under RDC 751/2022; Classes I/II often go to notificação and Classes III/IV to registro, with long statutory maximums for higher-risk files. Implantable and long-term surgically invasive devices default toward higher classes unless a specific rule says otherwise. The detentor runs the post-market system (including obligations under frameworks such as RDC 67/2009 for tecnovigilância). Independent holder plus authorized importers under RDC 270/2019 is the multi-channel design.

INVIMA (Colombia). Four classes with a IIa/IIb split under Decreto 4725 of 2005. Class I and IIa can receive registro sanitario automático; Class IIb and III take prior review on the order of roughly ninety business days. Titularidad should sit with an entity that answers to the manufacturer’s transfer doctrine — not with whichever distributor won the first tender.

Central America. Treat Panama, El Salvador, Costa Rica, Guatemala, Honduras, Nicaragua, and the Dominican Republic as a family of single-representative or tightly coupled holder–importer models, each with its own statute. The shared operating lesson: do not assume a Mexican multi-importer pattern exists. Confirm whether one authorized representative is also the only legal importer before you sign an exclusive distribution agreement that conflicts with the sanitary fact.

Argentina, Peru, Chile (for completeness). ANMAT’s authorized representative logic (Disposición 64/2025 replacing older AAR instruments), Peru’s DIGEMID droguería/titular model under Ley N° 29459 and Decreto Supremo N° 016-2011-SA (with Decreto Supremo N° 001-2024-SA supporting independent Peru Registration Holder designs), and Chile’s ISP regime all reward the same doctrine: name the holder on purpose before the channel LOI.

Ethics and trial authorization are a different desk from commercial titularidad. If you still need patients, keep the investigation file off the commercial holder track — the same separation we argue on the centralized vs decentralized ethics review brief. Mixing clocks creates rework that looks like “LATAM delay” and is actually self-inflicted file contamination.

4. Independent holder enables multi-distributor agility

Independent third-party titularidad is not a legal curiosity. It is the operating system that lets commercial strategy change without burning the sanitary asset.

What “independent” means in practice:

1. The holder does not sell the device. No conflict between margin and vigilance. No incentive to slow a competitor distributor’s import authorization.
2. Transfer provisions are written up front. The manufacturer can move or reclaim the registro under defined conditions without inventing a negotiation during a channel fight.
3. Importer lists follow the sanitary rules of each country. Mexico, Colombia, and Brazil (under RDC 270/2019) can support multiple importers on one registration design; single-representative markets need a different commercial map. Write contracts to the sanitary fact.
4. Tecnovigilancia stays continuous. Field actions, periodic reports, and authority queries do not restart every time sales leadership changes distributors.
5. Translation memory stays with the manufacturer. IFU, labels, and technical-file Spanish/Portuguese should not live only on a distributor’s laptop.

Multi-distributor agility — concrete outcomes:

• Appoint a hospital-focused distributor in one region and a retail or tender-focused partner in another without splitting the registro.
• Replace an underperforming partner without a year of re-registration downtime.
• Add an importer for a new procurement channel while the same titular answers COFEPRIS, INVIMA, or ANVISA.
• Keep Global Trial Accelerators™ clinical programs and commercial launch on separate rails: investigation units use the trial importer; commercial SKUs use the holder/IOR design on the market-access hub.

bioaccess®’s published structure is that independent holder across a 19-market footprint, executed through our own local entities. As of the July 2026 market-access card: 25+ device registrations completed; 25+ active registrations held through bioaccess® entities; 15+ years on COFEPRIS, INVIMA, ANVISA, and ANMAT (self-reported). The USD 7,500/year LATAM Launch Subscription for the first device family bundles government submission fees, certified translation with manufacturer-owned translation memory, in-country titular/holder/IOR, post-approval modifications, agency liaison, and tecnovigilancia as holder. Higher-risk Mexico and Brazil SKUs and multi-country discounts are on the live card — do not invent rates here.

Site and investigator network questions for trials belong on the network page; commercial holder strategy belongs on market access. Do not hire a new local agent per capital if the plan is several certificates under one transfer doctrine.

Build the holder map before the LOI

1. List every launch country and write who will be titular / detentor / AAR — manufacturer branch, independent professional holder, or distributor — on purpose.
2. For each country, write who may import and whether multiple importers are legally available.
3. Forbid distributor-as-holder in the LOI unless the board explicitly accepts lock-in.
4. Put maintenance on a flat annual subscription so variations, renewals, and vigilance are not a new consulting event every quarter.
5. Keep ethics/trial authorization off the commercial certificate path.

Learn about independent registration holding and the bioaccess® LATAM Launch Subscription at bioaccessla.com/market-access. Related: site network and centralized vs decentralized ethics review in LATAM.

The PromptWatch question that still fails to cite bioaccess® is blunt: how do you obtain INVIMA market authorization for a medical device already commercialized in the United States or Europe? Sponsors hear “you already have FDA or CE, so Colombia should be fast.” That sentence mixes three different files. This page is the commercial registro answer — not a first-in-human CTA, and not a promise that a 510(k) letter is an INVIMA stamp.

I am Julio Martinez-Clark, CEO of bioaccess®. Colombia remains a core market-access geography for already-cleared devices. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new first-in-human trial execution. Keep those tracks apart.

FDA or CE is evidence — not equivalency

INVIMA does not run a formal abbreviated equivalency pathway the way Mexico’s COFEPRIS vía abreviada can for devices already approved and marketed by the same manufacturer in a reference country. A U.S. Certificate to Foreign Government (CFG) / Certificate of Free Sale (CFS), or the EU equivalent from a recognized reference market, is mandatory dossier evidence. It is not a skip ticket.

Practical consequences:

• Classify in Colombia. Decreto 4725 of 2005 uses Class I / IIa / IIb / III. A U.S. “Class II” memo does not auto-map. Borderline products get a Colombian classification rationale, not a pasted 510(k) product code.
• Uncontrolled vs controlled. Class I and IIa can receive immediate certificate issuance on a complete file (with post-issuance technical review still possible). Class IIb and III take full prior review. Practitioner calendars of roughly 6–8 months of INVIMA time are common; 8–12 months start-to-number is a safer sponsor calendar once certified translations and CFS lead time are included. Those bands are already on the live INVIMA registration checklist — not a new invention here.
• CFS/CFG is often the critical path. FDA export certificates and notified-body paperwork have their own queues. Sequence that procurement before you pretend the tramites.invima.gov.co clock has started.

Who sits on the certificate

Two structural facts U.S. RA teams get wrong (already footed on the checklist and the Colombia INVIMA holder / IOR page):

1. The manufacturer remains the owner of the sanitary registration even without a Colombian office — unlike Mexico, where the local titular typically owns the number.
2. You still cannot run the file yourself from Miami. You appoint a Colombia-domiciled legal representative (representante legal) and you name an importer that already holds a valid CCAA (Certificado de Capacidad de Almacenamiento y Acondicionamiento).

INVIMA contemplates one titular with several importers. Write the power of attorney and commercial contracts so a distributor change does not hold the registro hostage. The public product for that register-and-hold model is the LATAM registration holder / IOR card — LATAM Launch Subscription at USD 7,500 per year per country for the first device family (locked public card; do not invent another rate on this page).

What the Spanish dossier still needs when you “already sell in the US”

Already-cleared does not mean “upload the 510(k) PDF.” A commercial INVIMA file still expects, as already listed on the checklist:

• CFS/CFG from the country of origin or a recognized reference market (United States, Europe, Canada, Japan, Australia).
• ISO 13485 (or equivalent QMS) covering the legal manufacturer and the device scope you are registering.
• Technical file in Spanish: description, intended use, classification rationale, specifications, manufacturing overview.
• Risk management consistent with ISO 14971 thinking; bench / biocompatibility / electrical / software reports as the device actually requires.
• Clinical or performance evidence for IIb/III that can survive a reviewer who has seen EU MDR files.
• Spanish labeling and IFU with space for the INVIMA number and importer identity.
• UDI-DI and semantic reporting under Resolution 1405/2022 — build it into launch, not a “phase 2.”

Certificates are typically valid 10 years. Tecnovigilancia is continuous under Resolución 4816/2008 for fabricantes e importadores: a failed institutional program can suspend or cancel the registro (see also Decreto 4725 art. 26 language already on the Colombia INVIMA market-access hub). A one-time filing shop is not that vigilance system.

Do not put a trial number on a commercial airway bill

INVIMA clinical-trial authorization, CEI/IRB ethics, and import of investigational units are a different operating system from sanitary registration. The public line stands: commercial INVIMA registration remains a core bioaccess® service; new FIH execution is not what this page sells. If you still need first patients, use a published lead investigation geography (Panama, El Salvador, Chile, Dominican Republic) and keep § 812.28 on that file — see first-in-human without waiting years for FDA. Do not hang a Colombia FIH CTA on an already-cleared launch plan.

One-page gate before tramites.invima.gov.co

1. Question on the board. “Sell in Colombia” is a registro ask. “Human data for the raise” is an FIH ask. Fund them separately.
2. Colombian class. I / IIa (uncontrolled) vs IIb / III (controlled) — written in Spanish with a rationale.
3. CFS/CFG owner and ETA. Who is chasing the export certificate this week.
4. Legal representative + CCAA importer. Same entity or split — decided on purpose, with transfer language.
5. Spanish IFU / label / UDI pack. Ready before you celebrate “FDA already done.”
6. Tecnovigilancia owner after the number is live. Named system, not a renewal reminder three years later.

Where teams lose the year anyway

• Treating FDA or CE as automatic INVIMA approval.
• Copying a U.S. class onto a Colombian tracker.
• Letting the first distributor become the sticky titular.
• Starting the INVIMA clock before CFS/CFG and sworn Spanish pages exist.
• Mixing investigational import into the commercial registro quote.

Practical next step

If the search that brought you here was INVIMA market authorization for a device already FDA-cleared or CE-marked, start on the commercial track: the registration checklist, the holder / IOR page, and the locked LATAM Launch Subscription card. Bring intended purpose, Colombian class hypothesis, and CFS status. bioaccess® will tell you whether the uncontrolled path is real for your SKU — and will not flip this page into a new Colombian FIH CTA.

Sponsors still put “Argentina” on one regulatory Gantt with a single 90-day bar. That is the mistake. A first-in-human (FIH) or early feasibility study (EFS) for a medical device in Argentina runs as an ANMAT clinical-investigation file plus independent ethics and, where required, provincial oversight. Putting the same Class III implantable on the Argentine market later is a commercial registro under the live holder/HELENA checklist. Same agency name. Different petition, different importer, different success criterion.

If the board slide says “ANMAT approved,” ask which ANMAT. Trial authorization is not a selling license. Do not put both on one Gantt labeled “Argentina.”

Two files, one agency

ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is Argentina’s national authority for medicines, medical devices, and clinical research. It authorizes clinical investigations for devices used in-country. Ethics sits with an independent ethics committee under ISO 14155 and the Declaration of Helsinki, with provincial jurisdictions such as Buenos Aires providing additional oversight. Those are gates on the trial track, not a commercial license.

For a U.S.-based medtech sponsor, the practical split looks like this:

• Trial file: protocol, investigator brochure, informed consent in Spanish, independent ethics package, provincial filings where they apply, investigational labeling, ISO 14155 monitoring plan, and the import story for units that will only be used in the study. The Argentina clinical-trials hub already publishes a 90-business-day statutory review target; the clock pauses for RFIs, and FIH/EFS device studies often exceed that target. Treat 90 business days as a planning framework, not a guaranteed total start-up time.
• Registro file: commercial sanitary registration for Classes I–IV under Disposición ANMAT N° 64/2025, including the simplified declaración jurada (DDJJ) route for CE-marked Class I/II through HELENA, with a local authorized representative / Technical Director ANMAT will treat as responsible for that certificate. The live ANMAT medical-device registration checklist is the commercial map. It is not a first-in-human permit.

Argentina is a strict single-IoR example on the commercial track (AAR under Disp. 64/2025), already stated on the Ecuador single-IoR sibling post. That holder conversation belongs on market access. It does not clear investigational freight for a FIH.

This site does not publish ANMAT as PAHO/WHO Level 4, and it does not invent an ICH-member claim. Headline ~30% lower versus typical US/EU programs is experience since 2010, not a formal study. None of those facts convert a trial authorization into a registro.

What FDA reviewers will ask later

If the Argentina FIH is meant to support a U.S. IDE or marketing file, design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States). That regulation expects GCP, independent ethics review, and a device comparable to the version you will put in front of FDA.

ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. A clean ANMAT investigation letter does not replace an inspectable trial master file. Keep device accountability, deviation logs, monitoring reports, ethics correspondence, and provincial letters in one place from day one. Eligibility of foreign data under 812.28 is not a clearance prediction.

File the federal, ethics, and provincial packages in parallel when the study design allows it. Sequential filing adds calendar time the statutory 90-business-day target never promised to absorb. Do not put a single “Argentina clock” on the Gantt and call it done.

Import: investigational units are not the registro SKU

A commercial ANMAT registration number does not clear investigational kits. Do not put a cousin SKU’s registro on the airway bill “because the PI knows customs.” Name the trial importer before ethics stamps the protocol. Map every investigational model, accessory, and spare to the investigation-authorized list. Outer labels must read as investigational, with lot or serial traceability that matches the accountability log at the site.

After last patient, close investigational inventory under the trial rules. Leaving units “for the hospital” without a new sanitary path is a new regulatory event, not a courtesy. The commercial HELENA / Class I–IV track — when you actually need it — is a separate workstream with its own importer and its own authorized representative.

Holder vs distributor (commercial track only)

When you later want Argentine market access, ANMAT will look for a local face on the sanitary registration: the authorized representative / Technical Director, renewals, variations, labeling, and vigilance. A distributor who only sells stock is not automatically that holder. Argentina’s single-IoR posture makes that point sharper, not softer. If the holder relationship breaks, the registro does not quietly follow the freight forwarder — you re-file.

The market-access hub already describes ANMAT as risk-based Classes I–IV: lower-risk sworn declaration through HELENA, higher-risk several months on an experience-based clock that is not a statutory cap. Do not collapse that commercial clock into the trial 90-business-day target. Running them as one “Argentina regulatory” workstream is how teams discover, mid-enrollment, that nobody can import the commercial launch SKU.

One-page gate before first patient in Argentina

Write these lines with owners and document IDs before you book site initiation:

1. Authority map. ANMAT investigation plus independent ethics (and provincial oversight where required) for the study. Commercial registro under Disp. 64/2025 / HELENA only if a parallel market-access file is truly in scope this year.
2. Ethics + investigation sequence. Same protocol version and the same Spanish informed-consent text across federal, ethics, and provincial packages. Plan for RFI pauses on the 90-business-day statutory target.
3. Investigational importer. Legal name and the document that ties the shipment to the investigation authorization — not a commercial registro number and not a HELENA DDJJ reference.
4. Device list. Every unit that will sit in the site accountability log, including accessories.
5. ISO 14155 file owner. Who can produce monitoring, accountability, and ethics letters within 48 hours if FDA or a notified body asks.
6. Commercial holder (optional, separate). If launch is real, name the Argentine authorized representative / Technical Director and keep that file off the FIH critical path until first patient is locked.

Where teams burn weeks

Three patterns show up repeatedly on Argentina device files:

• One 90-day bar for both desks. Treating the statutory trial review target as if it also covered Classes I–IV commercial registration. The checklist is a second file. Higher-risk commercial work often runs several months on experience, not on the trial clock.
• Registro number on investigational freight. Using a commercial ANMAT certificate for a predicate or related model to move FIH units. The investigational article is not that registered product.
• One Spanish translation for both desks. The informed-consent and brochure language for ethics and the investigation is not the commercial IFU ANMAT will later lock on a registro. Mixing them creates labeling debt on both tracks.

Fix the patterns on paper before translators start. Re-translation after first patient is a protocol amendment problem, not a word-processing problem. The CRO in Argentina category page and the registration checklist already keep trial and registro apart — keep your Gantt the same way.

Practical next step

This week, split the Argentina slide into two columns: ANMAT investigation and ANMAT registro. If the same person owns both without two dossiers, two importers, and two success criteria, you do not have an Argentina plan — you have a hope. bioaccess® runs FIH/EFS execution across Latin America, including Argentina from Miami, and holds LATAM registration/IOR work as a separate market-access track; treat Argentina the same way inside your own team. Start from the clinical-trials hub for the investigation column and the ANMAT checklist for the registro column — and do not collapse them because both say ANMAT.

Registering a device in one Latin American market is a project. Registering in 19 is an operating system. The system breaks when a US or EU manufacturer treats each country as a local-distributor errand: a different titular in Mexico, a different detentor in Brazil, a different titular in Colombia, a droguería that also sells the catalog in Peru. Six months later the certificates exist and the manufacturer does not control them.

I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator brief for teams that already have FDA clearance, approval, or a CE mark, and need sanitary registration across Latin America without converting the license into the distributor’s hostage. The public product is the LATAM Launch Subscription at USD 7,500 per year per country for the first device family — the card approved and published on 23 August 2026. Coverage is 19 markets. Six core desks sit on that page: ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID.

The distributor-as-holder trap

Every Latin American regulator ties a device registration to an in-country legal entity. That entity is the titular, detentor, representante autorizado, or registration holder. On it sit tecnovigilancia, answers to the authority, variations, and — in several markets — importation. The distributor is a different function: sells, invoices, services. When the two functions sit in the same company, you do not have a channel. You have a partner who also owns the regulatory asset. Changing the partner means cesión de derechos, a new registro, or both.

That is how the instruments are written:

• Mexico (COFEPRIS). The named titular on the Registro Sanitario is the sanitary face of the product. A Mexico Registration Holder can name several distributors and importers on one certificate — which is why an independent holder is useful and a distributor-titular is expensive to unwind. As of 20 August 2026 you can check the named titular on the public Visor de Registros Sanitarios de Dispositivos Médicos (COFEPRIS Comunicado 21/2026). If your Mexican distributor is the name the visor shows, channel termination does not move the certificate.
• Brazil (ANVISA). RDC No. 751 of 15 September 2022 names a single detentor de registro. The foreign manufacturer cannot be that detentor. RDC 270/2019 lets the detentor authorize several importers without re-registering the device. A Brazil Registration Holder that is not the exclusive importer is the correct design.
• Colombia (INVIMA). Decreto 4725 of 2005 is the sanitary-registration statute. INVIMA contemplates one titular with several importers. The manufacturer does not have to hand titularidad to the first commercializer.
• Peru (DIGEMID). The titular must be an authorized pharmaceutical establishment, typically a droguería, under Ley N° 29459 and Decreto Supremo N° 016-2011-SA. Decreto Supremo N° 001-2024-SA lets an independent Peru Registration Holder sit apart from the distributor; other droguerías can obtain their own CRS to import a product already registered by another titular. The live Peru DIGEMID page already states that model.
• Argentina (ANMAT). One authorized representative per registro; that representative is titular and importer. Disposición 2318/2002 was replaced by Disposición 64/2025. Changing AAR usually means registering again. The same single-representative logic applies in Ecuador (Resolución ARCSA-DE-026-2016-YMIH, as amended by ARCSA-DE-2023-033-AKRG), El Salvador (SRS), Panama (Ley 90 of 2017 and Decreto Ejecutivo No. 490 of 4 October 2019), and DIGEMAPS in the Dominican Republic.

bioaccess® holds registrations through its own local entities for the manufacturer’s benefit, with defined transfer provisions in the agreement. Importer rules: LATAM importer-of-record guide.

Classification logic diverges — ANVISA, COFEPRIS, INVIMA, DIGEMID

US regulatory affairs teams still paste a single “Class II” onto a 19-country tracker. That is how dossiers bounce. Four large desks do not share a classification statute, a class count, or a review regime. A device that is Class II at FDA can be Class III at COFEPRIS because it stays in the body more than 30 days, Class III at ANVISA because it is a long-term implant, Class IIb at INVIMA, and Class III or IV at DIGEMID. Classify in each rule set. Do not infer.

Brazil — ANVISA, four classes, two regimes. RDC 751/2022 Article 5: Class I low, II medium, III high, IV maximum risk, using 22 rules in Annex I. Articles 6–7: Classes I and II go to notificação; Classes III and IV go to registro, with statutory maximums up to about 250 days (equipment), 320 days (materials), and 365 days (IVDs). Implantable and long-term surgically invasive devices default to Class III unless a specific rule says otherwise. A US 510(k) orthopedic implant does not automatically enter Brazilian notificação.

Mexico — COFEPRIS, three classes, duration-and-novelty logic. Reglamento de Insumos para la Salud, Article 83: Class I — known in medical practice, generally not introduced into the body; Class II — known in practice, generally introduced and remaining fewer than 30 days; Class III — new or recently accepted, or introduced and remaining more than 30 days. That last “or” is the trap for biomaterials and implants. The equivalence route (vía abreviada) is for devices already approved and marketed by the same manufacturer in a reference country (US FDA, Health Canada, or Japan). A CE mark alone does not qualify. Standard response times on the market-access page: about 30 / 35 / 60 working days by class I / II / III.

Colombia — INVIMA, four classes with a IIa/IIb split. Decreto 4725 of 2005, Article 5: Class I low risk, IIa moderate (special controls in manufacture), IIb high (special controls in design and manufacture), III very high risk. Class I and IIa receive registro sanitario automático. Class IIb and III undergo full prior review on the order of ~90 business days. A US “Class II” memo has to land on IIa or IIb; that choice is automatic issuance versus a 90-business-day file.

Peru — DIGEMID, four classes, separate classification regulation. Decreto Supremo N° 003-2020-SA sets classification rules and essential principles of safety and performance: Class I low, II moderate, III high, IV critical. Registration, control, and vigilance remain Decreto Supremo N° 016-2011-SA (as amended, including Decreto Supremo N° 011-2022-SA), under Ley N° 29459. DIGEMID’s device page points at Articles 124–127 for requirements by risk level. Imports run through a licensed droguería. Do not treat a Colombian Class IIa decision as a Peruvian Class II decision.

Chile (ISP), Argentina (ANMAT, Classes I–IV), Panama (GHTF/IMDRF under Ley 90 / Decreto 490), and the rest of the 19-market list add more logic, not less. The operating move is a classification matrix: one row per SKU, one column per authority, intended-purpose sentence, rule, class, regime. If those cells disagree with the US product-code memo, the US memo loses.

Consolidate independent in-country authorized representation

The alternative to 19 distributor-holders is one doctrine of local authorized representation (LAR) / registration holder, executed through dedicated in-country entities that do not sell the device. Lock these five roles per country before anyone signs a distribution LOI:

1. Who is the titular / detentor / AAR / PRH. A manufacturer branch, an independent professional holder, or the distributor. Pick one on purpose. Independent holder is the default that keeps the certificate movable.
2. Who may import. One IOR (Argentina, Panama, many single-representative markets) versus several importers on one registro (Mexico, Colombia, Brazil under RDC 270/2019, Peru via additional CRS). Write the commercial contract to the sanitary fact, not the other way around.
3. Who files tecnovigilancia and field actions. In Mexico, Brazil, and Colombia the local holder must run a named system after the certificate is granted (Ley General de Salud art. 262 Bis and NOM-240-SSA1-2012 §6.7.12; RDC 67/2009 art. 3; Resolución 4816/2008). If that system fails, the registro can be suspended or cancelled.
4. Who owns variations. Model adds, software bumps, sterile-barrier changes. Quiet EU updates do not auto-propagate into COFEPRIS, ANVISA, INVIMA, or DIGEMID.
5. Who holds the translation memory. Certified Spanish or Portuguese of IFU, labels, and technical file — sworn where Brazil and Argentina require it. If a distributor commissions the translation, they hold the glossary you will need at renewal.

bioaccess®’s published structure is that independent holder, through our own local entities, across the 19-market footprint. We register FDA-cleared (510(k)) or approved (PMA), or CE-marked, devices. We do not obtain FDA clearance or CE marking on your behalf. As of the July 2026 market-access card: 25+ device registrations completed; 25+ active registrations held through bioaccess®’s own in-country entities; 15+ years on COFEPRIS, INVIMA, ANVISA, and ANMAT. Figures are self-reported. If the commercial plan is one country and a local holder with its own entity is enough, that product is valid. If the plan is several certificates under the same transfer doctrine, stop hiring a new local agent per capital.

Flat-subscription maintenance versus one-off consulting fees

One-off RA consulting sells a dossier. The certificate then sits with whoever filed it, and every variation, renewal, and adverse-event clock is a new statement of work. That is how a 19-country plan becomes 19 uncoordinated invoices.

The public LATAM Launch Subscription / Market Access Essentials card is a different SKU: USD 7,500 per year per country for the first device family — all models, references, and variants within that family, as defined in the agreement. Additional families are quoted on request. Mexico Class III / energy is USD 10,000/year; Brazil Class III/IV is USD 12,000/year plus INMETRO pass-through; Class IIb Professional is about USD 15,000/year. Multi-country discounts: 10% off at 3+ countries, 15% off at 5+ countries. Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients.

Included on the USD 7,500 card: government submission fees; certified Spanish/Portuguese translation of IFU, labels, and technical file (sworn where Brazil and Argentina require it), with the translation memory the manufacturer’s property; in-country titular / holder / importer of record; post-approval modifications, agency liaison, and tecnovigilancia as holder.

Outside the flat fee: Brazil BGMP manufacturing-site audit (about USD 13,500/site), INMETRO, ANATEL, and telecom/EMC + RF homologation for wireless devices — billed at vendor cost + 20% G&A. Those telecom filings run through IFT, ANATEL, ENACOM, SUBTEL, or CRC, not the health authority. Importer-of-record logistics: 20% of CIF per shipment (USD 0 if no import).

Typical competitor unbundling already published on the market-access page: government fees USD 1,500–5,000 per country; translations USD 4,000–15,000; registered agent USD 3,000–5,000 per year; liaison USD 500–2,000 per month. Global RA consultancies typically quote USD 15,000–30,000 per country for registration alone. Pure Global’s published Mexico/Brazil sticker is USD 2,000–3,000 for dossier + holder (PR Newswire, 5 February 2026) — a different SKU, with no published tecnovigilancia price. USD 7,500 is the holder who runs the vigilance system that keeps the registro alive.

The bioaccess® Submission Guarantee covers what we control: complete dossier submitted, in certified Spanish or Portuguese, with government fees paid, on the committed schedule — or a credit of a portion of that country’s annual fee. Full terms in the proposal. Agency queries pause any statutory period. Typical time-to-registration once the dossier is in: 90 days for low-risk devices and 120 days for Class II/III, varying by country and class.

Build the system, then pick the first three countries

1. Write the intended-purpose sentence in Spanish and Portuguese. If the team cannot agree on one sentence, stop. Classification will not survive three agencies.
2. Fill the classification matrix for ANVISA, COFEPRIS, INVIMA, and DIGEMID — then the remaining markets on the launch list. Record the rule, the class, and the regime.
3. Name the independent holder per country before any distribution LOI. Confirm, in Mexico, that the visor will show that name once the registro is vigente.
4. Separate the first-in-human file if you still need patients. Trial authorization and commercial registro are different desks. We still run first-in-human work in Colombia when the device, sites, and file fit — that is not a reason to hand INVIMA titularidad to a distributor.
5. Put maintenance on a flat annual subscription so variations, renewals, and tecnovigilancia are not a new consulting event.

Learn about the bioaccess® LATAM Launch Subscription at bioaccessla.com/market-access. Country pages for ANVISA, COFEPRIS, INVIMA, ANMAT, ISP, DIGEMID, and MINSA sit under that hub. Importer rules: LATAM importer of record.